

Metastatic triple-negative breast cancer (mTNBC) - Pipeline Insight, 2021

<https://marketpublishers.com/r/M35CD6064231EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: M35CD6064231EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Metastatic triple-negative breast cancer (mTNBC) - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Metastatic triple-negative breast cancer (mTNBC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Metastatic triple-negative breast cancer (mTNBC) Understanding

Metastatic triple-negative breast cancer (mTNBC): Overview

Breast cancer (BC) is the most common malignant neoplasm in females. Approximately 10–20% of BCs do not express estrogen and progesterone receptors and lack amplification/overexpression of the human epidermal growth factor 2 receptor (HER2); therefore, they are known as triple-negative breast cancers (TNBCs) and constitute an aggressive histologic subtype. Overall prognosis for patients with mTNBC is worse than for the other BC subtypes, and more effective therapeutic options are needed.

"Metastatic triple-negative breast cancer (mTNBC)- Pipeline Insight, 2021" report by

DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic triple-negative breast cancer (mTNBC) pipeline landscape is provided which includes the disease overview and Metastatic triple-negative breast cancer (mTNBC) treatment guidelines. The assessment part of the report embraces, in depth Metastatic triple-negative breast cancer (mTNBC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic triple-negative breast cancer (mTNBC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic triple-negative breast cancer (mTNBC) R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic triple-negative breast cancer (mTNBC).

Metastatic triple-negative breast cancer (mTNBC) Emerging Drugs Chapters

This segment of the Metastatic triple-negative breast cancer (mTNBC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic triple-negative breast cancer (mTNBC) Emerging Drugs

Trilaciclib: G1 Therapeutics

Trilaciclib is a first-in-class FDA-designated “Breakthrough Therapy” designed to improve outcomes for people with cancer who are treated with chemotherapy. In June 2019, the company announced preliminary overall survival (OS) data from a randomized Phase 2 trial, which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.

Leronlimab (PRO 140): CytoDyn

Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. CytoDyn is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer

Further product details are provided in the report.....

Metastatic triple-negative breast cancer (mTNBC): Therapeutic Assessment

This segment of the report provides insights about the different Metastatic triple-negative breast cancer (mTNBC) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Metastatic triple-negative breast cancer (mTNBC)

There are approx. 4+ key companies which are developing the therapies for Metastatic triple-negative breast cancer (mTNBC). The companies which have their Metastatic triple-negative breast cancer (mTNBC) drug candidates in the most advanced stage, i.e. phase II include, G1 Therapeutics.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Metastatic triple-negative breast cancer (mTNBC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic triple-negative breast cancer (mTNBC): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic triple-negative breast cancer

(mTNBC)therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic triple-negative breast cancer (mTNBC)drugs.

Metastatic triple-negative breast cancer (mTNBC)Report Insights

Metastatic triple-negative breast cancer (mTNBC)Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Metastatic triple-negative breast cancer (mTNBC)Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Metastatic triple-negative breast cancer (mTNBC)drugs?

How many Metastatic triple-negative breast cancer (mTNBC) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic triple-negative breast cancer (mTNBC)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic triple-negative breast cancer (mTNBC) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Metastatic triple-negative breast cancer (mTNBC) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

G1 Therapeutics

CytoDyn

Key Products

Trilaciclib

Leronlimab

Contents

Introduction

Executive Summary

Metastatic triple-negative breast cancer (mTNBC): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Metastatic triple-negative breast cancer (mTNBC)– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Metastatic triple-negative breast cancer (mTNBC)companies' collaborations, Licensing, Acquisition -Deal Value Trends

Metastatic triple-negative breast cancer (mTNBC)Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Trilaciclib: G1 Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Metastatic triple-negative breast cancer (mTNBC)Key Companies
Metastatic triple-negative breast cancer (mTNBC)Key Products
Metastatic triple-negative breast cancer (mTNBC)- Unmet Needs
Metastatic triple-negative breast cancer (mTNBC)- Market Drivers and Barriers
Metastatic triple-negative breast cancer (mTNBC)- Future Perspectives and Conclusion
Metastatic triple-negative breast cancer (mTNBC)Analyst Views
Metastatic triple-negative breast cancer (mTNBC)Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Metastatic triple-negative breast cancer (mTNBC)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Metastatic triple-negative breast cancer (mTNBC)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Metastatic triple-negative breast cancer (mTNBC) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/M35CD6064231EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M35CD6064231EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970